Ablaze Pharmaceuticals announced the initiation of a development and manufacturing services agreement with Yonghe Pharmaceutical Technology Co (Yonghe) to develop a series of targeted radiopharmaceutical therapy (TRT) products. Under the agreement. Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze from pharmaceutical research and preclinical activities to clinical studies.

"This agreement with Yonghe represents a significant step for Ablaze in our efforts to optimise our preclinical and clinical development programme for target radiopharmaceutical therapy," said Dr Tiecheng Qiao, President and Chief Executive Officer of Ablaze. "Target radiopharmaceutical therapy is a proven approach to treating many cancers. We are excited about this opportunity to bring this novel class of TRT products to benefit patients in China."

"We are glad to support Ablaze and its targeted radiopharmaceutical therapy programs. TRT offers the potential to play an important role in the fight against cancer, we seek to provide a robust and efficient radiopharmaceutical manufacture, testing, and supply process for our partners from early-stage development through commercialisation," said Bo Lin, Chairman, Yonghe.